KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Receivables (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Receivables for 16 consecutive years, with $90.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 298.39% to $90.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $128.1 million through Dec 2025, up 72.49% year-over-year, with the annual reading at $128.1 million for FY2025, 72.49% up from the prior year.
  • Change in Receivables for Q4 2025 was $90.5 million at Halozyme Therapeutics, up from $29.7 million in the prior quarter.
  • The five-year high for Change in Receivables was $90.5 million in Q4 2025, with the low at -$41.1 million in Q3 2021.
  • Average Change in Receivables over 5 years is $14.1 million, with a median of $14.3 million recorded in 2023.
  • Peak annual rise in Change in Receivables hit 746.9% in 2021, while the deepest fall reached 263.41% in 2021.
  • Over 5 years, Change in Receivables stood at -$21.1 million in 2021, then surged by 136.71% to $7.8 million in 2022, then skyrocketed by 117.73% to $16.9 million in 2023, then skyrocketed by 34.51% to $22.7 million in 2024, then soared by 298.39% to $90.5 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $90.5 million, $29.7 million, and $11.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.